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The pro-tumoral diversion of macrophages remains an unresolved paradox of tumor immunology and a
conceptual gap in the understanding of tumor biology. Goossens et al. (2019) identify a new level of cross-
regulation by which tumors increase the membrane cholesterol efflux of macrophages to enhance their
pro-tumoral activation in response to IL-4.It is well known that in many human solid
tumors, a high number of tumor-associ-
ated macrophages (TAMs) is associated
with poor prognosis (Bingle et al., 2002),
although in few types of cancers,
including ovarian cancer, macrophage
content has been reported as a favorable
prognostic index. In addition to their num-
ber, the M1 versus M2 paradigm of
macrophage polarization has established
that it is the activation state of TAMs that
is a critical determinant of tumor progres-
sion. In particular, it has been shown that
relevant pathways exist by which tumors
promote the M2-like, tumor-promoting
or the M1-like, tumor-inhibiting pheno-
types of macrophages. For example, it is
believed that IL-4 signaling leads to an
M2-polarizing, pro-tumoral effect, whileIFNg promotes the M1-polarizing, anti-tu-
moral action of macrophages (Porta et al.,
2018). Accumulating evidence indicates
that the phenotype of TAMs is intricately
regulated by several additional actors,
including microphysiological conditions
(e.g., hypoxia, pH, and glucose levels)
and point to myeloid cell metabolism
as an essential part of the signaling
network that orchestrates their pheno-
type. As examples, while the immunosup-
pressive functions of myeloid-derived
suppressor cells (MDSCs) are supported
by increased fatty acid uptake and re-
verted upon silencing of the fatty acid
translocase CD36 (Al-Khami et al.,
2017), mice with genetic deletion of the
Abcg1 gene, a cholesterol efflux trans-
porter, showed strong resistance to tumorgrowth in models of bladder cancer and
melanoma (Sag et al., 2015). Metabolic
events not only influence the activation
and polarization state of terminally
mature cells but may also affect the
fate of myeloid progenitors. Indeed, the
retinoic-acid related orphan receptor
(RORC1/RORg), which requires choles-
terol precursors and metabolites (i.e.,
oxysterols) as coactivators, was recently
shown to orchestrate emergency myelo-
poiesis in human and mouse tumor
bearers, supporting both expansion
of MDSCs and differentiation of M2-
polarized, pro-tumor TAMs (Strauss
et al., 2015).
This evidence supports a direct connec-
tion between lipidmetabolismand the pro-
tumoral differentiation of myeloid cells,
Figure 1. Alteration of Membrane Cholesterol Efflux Controls the Phenotye of TAMs
Tumor-derived hyaluronic acid enhances membrane cholesterol efflux from TAMs to amplify their IL-4-
dependent and tumor-promoting M2 polarization in response to IL-4. By contrast, enhanced cholesterol
efflux hinders IFNg-mediated gene transcription, supporting a M1 to M2 skewing of TAM phenotype.
Enhanced IL-4 activity results in increased activation of STAT6 and PI3K-Akt signaling, which drive
expression of immunosuppressive genes (i.e., Arg1). Cancer cells acquire cholesterol from TAMs, which
express high levels of the ABCA1 and ABCG1, thus diminishing their energetic cost for cholesterol
biosynthesis. Finally, high levels of circulating cholesterol may impair cholesterol efflux, restoring in-
flammatory responses by TAMs.
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Previewswhich represents the focus of the study by
Goossens et al. (2019). By using a mouse
model of ovarian cancer, characterized
by cancer cell colonization of the perito-
neum, the authors show that tumor pro-
gression promotes a gradual replacement
of resident peritoneal macrophages (em-




an event was paralleled by an early
enhanced expression of pro-inflammatory
genes (5 days after tumor cells implanta-
tion), assessed in a bulk TAM population,
which declined at later stages of tumor
progression (21 days after tumor cell im-
plantation). These later stages were also
marked by increased expression in TAMs
of genes encoding for cholesterol efflux
transporters, such as ABCA1 and
ABCG1, displaying a reduction in the
number of cholesterol-rich membrane
micro-domains. Further, the authors
observed that the extracellular matrix
component hyaluronic acid, released by
cancer cells, promoted depletion of mem-
brane cholesterol content in macrophages
and consequently increased IL-4R activity,
including STAT6 and PI3K-mTORC2-Akt
signaling, while impairing expression of
IFNg-induced genes. However, they did
not clarify how HA sensing by macro-
phages occurs and how this is connected
to the reprogramming of IL-4R- and IFN-
gR-dependent signaling activity. Nor did
the authors identify the intratumoralsource of IL-4. Despite these limitations,
the tumor-promoting role of IL-4 was
demonstrated in vivo using a monoclonal
antibody against the IL-4 receptor (aIL-
4ra), which recapitulated the tumor growth
inhibition observed in chimeric mice
harboring hematopoietic genetic defi-
ciency of either STAT6 or PI3K.
The results reported by Goossens et al.
(2019) are in line with the observation that
membrane cholesterol levels strongly
affect receptor stability and signaling
pathways. They also dovetail with previ-
ous reports showing that while ABCA1-
deficient macrophages become hyperre-
sponsive to M1-polarizing signals (e.g.,
TLR4 agonists), they acquire hyporespon-
siveness toM2-polarizing signals (e.g., IL-
4 and IL-13) (Pradel et al., 2009). The pos-
sibility of acquiring cholesterol from
TAMs, which display high activity of the
ABCA1 and ABCG1 efflux transporters,
offers a clear energetic advantage to can-
cer cells. Indeed, this ‘‘feeding’’ of tumor
cells by TAMs can diminish the energetic
costs of tumor cells, as it reduces the
need for their own endogenous choles-
terol biosynthesis. But, importantly, the
effect on macrophage reprogramming
by membrane cholesterol depletion is re-
verted by the addition of exogenous
cholesterol. In addition, alterations in
cholesterol metabolism may affect
metastasis formation by widely altering
functions of other types of innate and
adaptive immune cells (Baek et al.,
2017). Moreover, HA-mediated inhibitionof IFNg-inducible genes might have
relevant impact on current anticancer
immunotherapies, since several immuno-
suppressivemolecules (e.g., PD-L1, indo-
leamine 2,3 dyoxygenase, and NOS2) are
prototypically induced by IFNg, and clin-
ical-grade immune checkpoint inhibitors
(i.e., anti-PD-L1 and anti-CTLA4) entrust
their antitumor activity on the reactivation
of Th1-mediated antitumor immunity
(Porta et al., 2018). However, while pre-
clinical data might support a clinical role
for serum cholesterol in cancer, this has
not been defined yet. Some epidemiolog-
ical cohorts suggest an increased risk and
more recurrences of some types of malig-
nancies such as prostate cancer, and
some trials suggest a risk reduction by
using statins in several cancers such as
colon cancer, melanoma, endometrial
cancer, breast cancer, and lymphomas
(Nielsen et al., 2013). On the other hand,
other trials exclude a direct role of choles-
terol and of the lowering of cholesterol on
the risk of cancer (Kuzu et al., 2016).
Similar debatable findings are recently
found also for a diet with an increased
fat intake (Christ and Latz, 2019). All these
data can be hampered on both sides of
the argument by several factors, such as
the retrospective nature of the observa-
tions, the non-controlled analyses for
multifactorial disease, and the association
to non-cancer related deaths, rendering
an interpretation of the role of cholesterol
homeostasis in cancer still an open clin-
ical issue. The work by Goossens et al.
(2019) has the merit to emphasize choles-
terol metabolism as a crucial crossroads
in the regulation of immune responses
(Figure 1) and urges new efforts to clarify
the interplay between lipid metabolism
and antitumor immunity.ACKNOWLEDGMENTS
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In this issue of Cell Metabolism, Du et al. (2019) describe how insulin-like growth factor 2 (IGF-2), a protein
with structural similarity to insulin, induces an anti-inflammatory phenotype in maturing macrophages
through reprogramming of their mitochondrial metabolism. These anti-inflammatory properties are main-
tained upon secondary stimulation and alleviate experimental autoimmune encephalomyelitis (EAE) in vivo.Macrophages have important roles for tis-
sue repair and regeneration aswell as host
defense components against invading mi-
croorganisms. They are plastic cells that
can differentiate and adapt toward spe-
cific phenotypes: a more proinflammatory
phenotype is needed for host defense,
whereas an anti-inflammatory or regulato-
ry phenotype is necessary for the resolu-
tion of inflammation and tissue repair.
These processes are under complex regu-
lation. Much has been learned about
the capacity of exogenous (especially
microbial) and endogenous ligands to
activate immunological, metabolic, and
epigenetic pathways resulting in a pro-
inflammatory phenotype (Lachmandaset al., 2016). However, much less is known
about whether similar processes are also
important for the induction of a regulatory
phenotype of macrophages. In this issue
of Cell Metabolism, Du, Lin, and col-
leagues take an important step toward
understanding these processes by
describing that insulin-like growth factor
2 (IGF-2), a protein hormonewith structural
similarity to insulin, induces a strong
anti-inflammatory phenotype in maturing
macrophages through reprogramming of
their mitochondrial metabolism (Du et al.,
2019). These anti-inflammatory properties
are maintained upon secondary stimula-
tion and alleviate experimental autoim-
mune encephalomyelitis (EAE) in vivo.The immune system is constantly chal-
lenged by exogenous and endogenous
stimuli. In recent years, it has been shown
that not only lymphocytes but alsomyeloid
cells from the innate immune system are
able to ‘‘remember’’ the stimuli they
encounter and undergo functional meta-
bolic and epigenetic reprogramming,
facilitating secondary inflammatory or
anti-inflammatory responses upon restim-
ulation (Netea et al., 2016). These innate
immune memory mechanisms (also
termed ‘‘trained immunity’’) were originally
described to be triggered by microbial
stimuli, such as LPS from Gram-negative
bacteria or b-glucan from fungi, that
respectively skew macrophages toward
